Submit Manuscript  

Article Details


Does the Oxazolidinone Derivatives Constitute a Functional Approach for Cancer Therapy?

[ Vol. 7 , Issue. 2 ]

Author(s):

Eduardo Augusto Vasconcelos de Freitas Ramalho*, Marina Galdino da Rocha Pitta, Hernando de Barros Siqueira Neto and Ivan da Rocha Pitta   Pages 95 - 106 ( 12 )

Abstract:


In the last four decades, the emphasis was laid on the research of small organic molecules with potential anti-cancer activity. Linezolid was the first oxazolidinone derivative approved by FDA for MRSA treatment. Despite its major role in antimicrobial activity, these molecules display other properties, also serving as an antitumor agent. The importance of drug repurposing could be highlighted by the use of Oxazolidinone derivatives in pre-clinical studies, which are able to act through different pathways, such as partial agonist of transcription factor PPAR-γ, an inhibitor of key enzymes related to hormone-dependent disorders and even on sphingolipid metabolism as well. The purpose of this short review is to discuss the application of oxazolidinone derivatives as an antitumor agent by highlighting the most promising molecules studied by many research groups worldwide. Main biological activity against several tumor cell lines, including hematopoietic and solid cancer cell lines have been discussed. In addition, this study intends to report how different types of oxazolidinone derivatives can act as antitumor agents describing their distinct mechanisms of action based on their targets.

Keywords:

Cancer, ceramide, oxazolidinone, PPAR, therapeutic, 17β-HSD.

Affiliation:

Nucleus of Research in Therapeutic Innovation, Federal University of Pernambuco, Recife, P.O. Box 50670-901, Nucleus of Research in Therapeutic Innovation, Federal University of Pernambuco, Recife, P.O. Box 50670-901, Nucleus of Research in Therapeutic Innovation, Federal University of Pernambuco, Recife, P.O. Box 50670-901, Nucleus of Research in Therapeutic Innovation, Federal University of Pernambuco, Recife, P.O. Box 50670-901

Graphical Abstract:



Read Full-Text article